da-8010
Small moleculeexperimental
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 2016 (NCT02821312)
Timeline
Indications
Mechanism of action
- Muscarinic acetylcholine receptor M3ANTAGONIST
CHRM3 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- da-8010
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05992428 | Phase 1 | Aug 22, 2023 | Dong-A Pharmaceutical |
| NCT05991401 | Phase 1 | Aug 18, 2023 | Dong-A Pharmaceutical |
| NCT05812417 | Phase 1 | Apr 10, 2023 | Dong-A Pharmaceutical |
| NCT05282069 | Phase 3 | May 12, 2022 | Dong-A Pharmaceutical |
| NCT04686825 | Phase 1 | Dec 23, 2020 | Dong-A Pharmaceutical, Seoul National University |
| NCT03566134 | Phase 2 | Jul 10, 2018 | Dong-A Pharmaceutical |
| NCT02821312 | Phase 1 | Jun 1, 2016 | Dong-A Pharmaceutical |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dong-A Pharmaceutical | For profit | 7 | 7 | 3 | 2016 |
| Seoul National University | Academic/Hospital | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1